OPEN END TURBO LONG - BB BIOTECH N Stock

Certificat

DE000MD3NKA6

Real-time Bid/Ask 03:04:35 2024-07-11 am EDT
1.13 EUR / 1.15 EUR +6.54% Intraday chart for OPEN END TURBO LONG - BB BIOTECH N
Current month+5.94%
1 month+12.63%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-07-10 1.07 +7.00%
24-07-09 1 +7.53%
24-07-08 0.93 -1.06%
24-07-05 0.94 +1.08%
24-07-04 0.93 +1.09%

Delayed Quote Börse Stuttgart

Last update July 10, 2024 at 05:53 am EDT

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellCALL
Underlying BB BIOTECH AG
Issuer Morgan Stanley
WKN MD3NKA
ISINDE000MD3NKA6
Date issued 2022-04-14
Strike 30.73 CHF
Maturity Unlimited
Parity 10 : 1
Emission price 3.38
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 3.54
Lowest since issue 0.52
Spread 0.02
Spread %1.74%

Company Profile

BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Company’s portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.
Sector
-
More about the company

Ratings for BB Biotech AG

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: BB Biotech AG

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
41.4 CHF
Average target price
47.7 CHF
Spread / Average Target
+15.22%
Consensus